APO Research
Talk to an analyst

APO RESEARCH · REPORT

Management of Antithrombin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Management of Antithrombin Market Outlook and Growth Opportunities 2026

27 December 2025190 pages

Choose your research edition.

Industry ResearchManagement of Antithrombin Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Management of Antithrombin Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Management of Antithrombin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Management of Antithrombin Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Management of Antithrombin Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Management of Antithrombin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Management of Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Management of Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Management of Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Management of Antithrombin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Management of Antithrombin market include Takeda, Grifols, Scripps Laboratories Inc., rEVO Biologics Inc., Lee Biosolutions, Kedrion S.p.A. and CSL Limited, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Management of Antithrombin market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Management of Antithrombin and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Management of Antithrombin revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Management of Antithrombin market.

Management of Antithrombin Segment by Company

Takeda

Grifols

Scripps Laboratories Inc.

rEVO Biologics Inc.

Lee Biosolutions

Kedrion S.p.A.

CSL Limited

Management of Antithrombin Segment by Type

Liquid

Lyophilized

Management of Antithrombin Segment by Application

Diagnostics

Therapeutics

Research

Management of Antithrombin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Management of Antithrombin status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Management of Antithrombin key companies, revenue, market share, and recent developments.

3. To split the Management of Antithrombin breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Management of Antithrombin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Management of Antithrombin significant trends, drivers, influence factors in global and regions.

6. To analyze Management of Antithrombin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Management of Antithrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Management of Antithrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Management of Antithrombin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Management of Antithrombin industry.

Chapter 3: Detailed analysis of Management of Antithrombin company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Management of Antithrombin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Management of Antithrombin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Management of Antithrombin Industry Trends Table 2. Management of Antithrombin Industry Drivers Table 3. Management of Antithrombin Industry Opportunities and Challenges Table 4. Management of Antithrombin Industry Restraints Table 5. Global Management of Antithrombin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Management of Antithrombin Revenue Share by Company (2021-2026) Table 7. Global Management of Antithrombin Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Management of Antithrombin Key Company Manufacturing Base & Headquarters Table 9. Global Management of Antithrombin Company, Product Type & Application Table 10. Global Management of Antithrombin Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Management of Antithrombin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liquid Table 15. Significant Companies of Lyophilized Table 16. Global Management of Antithrombin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Management of Antithrombin Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Management of Antithrombin Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Management of Antithrombin Sales Value Share by Type (2021-2026) Table 20. Global Management of Antithrombin Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Diagnostics Table 22. Significant Companies of Therapeutics Table 23. Significant Companies of Research Table 24. Global Management of Antithrombin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Management of Antithrombin Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Management of Antithrombin Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Management of Antithrombin Sales Value Share by Application (2021-2026) Table 28. Global Management of Antithrombin Sales Value Share by Application (2027-2032) Table 29. Global Management of Antithrombin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Management of Antithrombin Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Management of Antithrombin Sales Value Share by Region (2021-2026) Table 32. Global Management of Antithrombin Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Management of Antithrombin Sales Value Share by Region (2027-2032) Table 34. Global Management of Antithrombin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Management of Antithrombin Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Management of Antithrombin Sales Value Market Share by Country (2021-2026) Table 37. Global Management of Antithrombin Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Management of Antithrombin Sales Value Market Share by Country (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Management of Antithrombin Product Portfolio Table 43. Takeda Recent Development Table 44. Grifols Company Information Table 45. Grifols Business Overview Table 46. Grifols Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Grifols Management of Antithrombin Product Portfolio Table 48. Grifols Recent Development Table 49. Scripps Laboratories Inc. Company Information Table 50. Scripps Laboratories Inc. Business Overview Table 51. Scripps Laboratories Inc. Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Scripps Laboratories Inc. Management of Antithrombin Product Portfolio Table 53. Scripps Laboratories Inc. Recent Development Table 54. rEVO Biologics Inc. Company Information Table 55. rEVO Biologics Inc. Business Overview Table 56. rEVO Biologics Inc. Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. rEVO Biologics Inc. Management of Antithrombin Product Portfolio Table 58. rEVO Biologics Inc. Recent Development Table 59. Lee Biosolutions Company Information Table 60. Lee Biosolutions Business Overview Table 61. Lee Biosolutions Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Lee Biosolutions Management of Antithrombin Product Portfolio Table 63. Lee Biosolutions Recent Development Table 64. Kedrion S.p.A. Company Information Table 65. Kedrion S.p.A. Business Overview Table 66. Kedrion S.p.A. Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Kedrion S.p.A. Management of Antithrombin Product Portfolio Table 68. Kedrion S.p.A. Recent Development Table 69. CSL Limited Company Information Table 70. CSL Limited Business Overview Table 71. CSL Limited Management of Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. CSL Limited Management of Antithrombin Product Portfolio Table 73. CSL Limited Recent Development Table 74. Research Programs/Design for This Report Table 75. Authors List of This Report Table 76. Secondary Sources Table 77. Primary Sources List of Figures Figure 1. Management of Antithrombin Product Image Figure 2. Global Management of Antithrombin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Management of Antithrombin Market Size (2021-2032) & (US$ Million) Figure 4. Global Management of Antithrombin Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liquid Image Figure 8. Lyophilized Image Figure 9. Global Management of Antithrombin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Management of Antithrombin Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Management of Antithrombin Sales Value Share by Type (2021-2032) Figure 12. Diagnostics Image Figure 13. Therapeutics Image Figure 14. Research Image Figure 15. Global Management of Antithrombin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Management of Antithrombin Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Management of Antithrombin Sales Value Share by Application (2021-2032) Figure 18. Global Management of Antithrombin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Management of Antithrombin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Management of Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 21. North America Management of Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Management of Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Management of Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Management of Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Management of Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Management of Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 27. South America Management of Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Management of Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Management of Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Management of Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Management of Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Management of Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Lyophilized
Applications
  • Diagnostics
  • Therapeutics
  • Research
Companies covered
  • Takeda
  • Grifols
  • Scripps Laboratories Inc.
  • rEVO Biologics Inc.
  • Lee Biosolutions
  • Kedrion S.p.A.
  • CSL Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Management of Antithrombin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Management of Antithrombin Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Management of Antithrombin Market Dynamics
  1. 2.1 Management of Antithrombin Industry Trends
  2. 2.2 Management of Antithrombin Industry Drivers
  3. 2.3 Management of Antithrombin Industry Opportunities and Challenges
  4. 2.4 Management of Antithrombin Industry Restraints
3 Management of Antithrombin Market by Company
  1. 3.1 Global Management of Antithrombin Company Revenue Ranking in 2025
  2. 3.2 Global Management of Antithrombin Revenue by Company (2021-2026)
  3. 3.3 Global Management of Antithrombin Company Ranking (2024-2026)
  4. 3.4 Global Management of Antithrombin Company Manufacturing Base and Headquarters
  5. 3.5 Global Management of Antithrombin Company Product Type and Application
  6. 3.6 Global Management of Antithrombin Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Management of Antithrombin Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Management of Antithrombin Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Management of Antithrombin Market by Type
  1. 4.1 Management of Antithrombin Type Introduction
  2. 4.1.1 Liquid
  3. 4.1.2 Lyophilized
  4. 4.2 Global Management of Antithrombin Sales Value by Type
  5. 4.2.1 Global Management of Antithrombin Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Management of Antithrombin Sales Value by Type (2021-2032)
  7. 4.2.3 Global Management of Antithrombin Sales Value Share by Type (2021-2032)
5 Management of Antithrombin Market by Application
  1. 5.1 Management of Antithrombin Application Introduction
  2. 5.1.1 Diagnostics
  3. 5.1.2 Therapeutics
  4. 5.1.3 Research
  5. 5.2 Global Management of Antithrombin Sales Value by Application
  6. 5.2.1 Global Management of Antithrombin Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Management of Antithrombin Sales Value by Application (2021-2032)
  8. 5.2.3 Global Management of Antithrombin Sales Value Share by Application (2021-2032)
6 Management of Antithrombin Regional Value Analysis
  1. 6.1 Global Management of Antithrombin Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Management of Antithrombin Sales Value by Region (2021-2032)
  3. 6.2.1 Global Management of Antithrombin Sales Value by Region: 2021-2026
  4. 6.2.2 Global Management of Antithrombin Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Management of Antithrombin Sales Value (2021-2032)
  7. 6.3.2 North America Management of Antithrombin Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Management of Antithrombin Sales Value (2021-2032)
  10. 6.4.2 Europe Management of Antithrombin Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Management of Antithrombin Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Management of Antithrombin Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Management of Antithrombin Sales Value (2021-2032)
  16. 6.6.2 South America Management of Antithrombin Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Management of Antithrombin Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Management of Antithrombin Sales Value Share by Country, 2025 VS 2032
7 Management of Antithrombin Country-level Value Analysis
  1. 7.1 Global Management of Antithrombin Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Management of Antithrombin Sales Value by Country (2021-2032)
  3. 7.2.1 Global Management of Antithrombin Sales Value by Country (2021-2026)
  4. 7.2.2 Global Management of Antithrombin Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Management of Antithrombin Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Management of Antithrombin Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Management of Antithrombin Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Management of Antithrombin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Management of Antithrombin Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Management of Antithrombin Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Management of Antithrombin Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Management of Antithrombin Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Management of Antithrombin Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Management of Antithrombin Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Management of Antithrombin Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Management of Antithrombin Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Management of Antithrombin Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Management of Antithrombin Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Management of Antithrombin Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Management of Antithrombin Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Management of Antithrombin Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Management of Antithrombin Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Management of Antithrombin Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Management of Antithrombin Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Management of Antithrombin Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Management of Antithrombin Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Management of Antithrombin Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Management of Antithrombin Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Management of Antithrombin Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Management of Antithrombin Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Management of Antithrombin Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Management of Antithrombin Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Management of Antithrombin Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Management of Antithrombin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Management of Antithrombin Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Management of Antithrombin Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Grifols
  8. 8.2.1 Grifols Company Information
  9. 8.2.2 Grifols Business Overview
  10. 8.2.3 Grifols Management of Antithrombin Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Grifols Management of Antithrombin Product Portfolio
  12. 8.2.5 Grifols Recent Developments
  13. 8.3 Scripps Laboratories Inc.
  14. 8.3.1 Scripps Laboratories Inc. Company Information
  15. 8.3.2 Scripps Laboratories Inc. Business Overview
  16. 8.3.3 Scripps Laboratories Inc. Management of Antithrombin Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Scripps Laboratories Inc. Management of Antithrombin Product Portfolio
  18. 8.3.5 Scripps Laboratories Inc. Recent Developments
  19. 8.4 rEVO Biologics Inc.
  20. 8.4.1 rEVO Biologics Inc. Company Information
  21. 8.4.2 rEVO Biologics Inc. Business Overview
  22. 8.4.3 rEVO Biologics Inc. Management of Antithrombin Revenue and Gross Margin (2021-2026)
  23. 8.4.4 rEVO Biologics Inc. Management of Antithrombin Product Portfolio
  24. 8.4.5 rEVO Biologics Inc. Recent Developments
  25. 8.5 Lee Biosolutions
  26. 8.5.1 Lee Biosolutions Company Information
  27. 8.5.2 Lee Biosolutions Business Overview
  28. 8.5.3 Lee Biosolutions Management of Antithrombin Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lee Biosolutions Management of Antithrombin Product Portfolio
  30. 8.5.5 Lee Biosolutions Recent Developments
  31. 8.6 Kedrion S.p.A.
  32. 8.6.1 Kedrion S.p.A. Company Information
  33. 8.6.2 Kedrion S.p.A. Business Overview
  34. 8.6.3 Kedrion S.p.A. Management of Antithrombin Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kedrion S.p.A. Management of Antithrombin Product Portfolio
  36. 8.6.5 Kedrion S.p.A. Recent Developments
  37. 8.7 CSL Limited
  38. 8.7.1 CSL Limited Company Information
  39. 8.7.2 CSL Limited Business Overview
  40. 8.7.3 CSL Limited Management of Antithrombin Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CSL Limited Management of Antithrombin Product Portfolio
  42. 8.7.5 CSL Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst